P2X7 receptor activation impairs exogenous MHC class I oligopeptides presentation in antigen presenting cells

PLoS One. 2013 Aug 5;8(8):e70577. doi: 10.1371/journal.pone.0070577. Print 2013.

Abstract

Major histocompatibility complex class I (MHC I) on antigen presenting cells (APCs) is a potent molecule to activate CD8(+) T cells and initiate immunity. P2X7 receptors (P2X7Rs) are present on the plasma membrane of APCs to sense the extracellular danger signal adenosine-5'-triphosphate (ATP). P2X7R activates the inflammasome and the release of IL-1β in macrophages and other immune cells to initiate the inflammatory response. Here we show that P2X7R stimulation by ATP in APCs decreased the amount of MHC I at the plasma membrane. Specific antagonism or genetic ablation of P2X7R inhibited the effects of ATP on levels of cellular MHC I. Furthermore, P2X7R stimulation was able to inhibit activation of CD8(+) T cells via specific MHC I-oligopeptide complexes. Our study suggests that P2X7R activation on APCs is a novel inhibitor of adaptive CD8(+) T cell immunity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigen-Presenting Cells / drug effects
  • Antigen-Presenting Cells / metabolism*
  • CD8-Positive T-Lymphocytes / metabolism
  • Cells, Cultured
  • Female
  • Genes, MHC Class I*
  • Interleukin-1beta / metabolism
  • Macrophages / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Oligopeptides / metabolism*
  • Purinergic P2X Receptor Antagonists / pharmacology
  • Pyridines / pharmacology
  • Receptors, Purinergic P2X7 / genetics
  • Receptors, Purinergic P2X7 / metabolism*
  • Tetrazoles / pharmacology

Substances

  • 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine
  • Interleukin-1beta
  • Oligopeptides
  • Purinergic P2X Receptor Antagonists
  • Pyridines
  • Receptors, Purinergic P2X7
  • Tetrazoles

Grants and funding

This work was supported by grants from Plan Nacional I+D+I 2008–2011-Instituto Salud Carlos III-Fondo Europeo de Desarrollo Regional (EMER07/049 and PI09/0120)and Fundación Séneca (11922/PI/09), managed by Fundación Formación Investigación Sanitaria Región de Murcia (FFIS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.